TomP1, try to be more objective, TPIV BOD's recognize concerns in management performance and are working it. Although I have communicated this in the past, BOD action has nothing to do with my connections to the TPIV BOD, it has everything to do with Glynn Wilson's very poor performance and shareholder value destruction over the years. This is further complicated by the fact Wilson repriced warrants for the 2015 private investors during the last round of financing this summer without regard to other existing shareholders. There are questions concerning the 2015 private investors selling shares and/or warrants since the 2015 financing and the downward impact on share price since that time. Combine the above activity with the very long term published interviews, management presentations, press releases and other forms of communications and promotion where milestones/commitments have been continuously amended and schedules regarding real scientific data and progress have never been met and you have the basis for SEC complaints and legal action. Throwing gasoling of the fire is the potential collateral damage from questionable relationship people associated with TPIV may have with Neurotrope (NTRP) and other entities associated with NTRP as outlined in a published SeekingAlpha article, the article mentioned TPIV. I was shocked when I read this article, why was this never communicated to TPIV shareholders. So yes much to question about TPIV management and BOD over the years and they may get to answer questions the hard way. Finally all this happened under ther reign of the current CEO, Glynn Wilson. Irrespective of legal action and complaints the above is wrong, flat out wrong and unethical, financially and emotionally destructive to people who put their trust, faith and financial future in real companies and the market. Why would any CEO or anyone get to keep their job after doing the above, but yet we have it in modern day TPIV and its CEO Glynn Wilson. What is worse, Wilson will not recognize that he failed and resign which leads me to draw conclusions to the sociopath behavior of Bernie Madoff, how can a CEO like Wilson survive. Glynn, let me educate here a bit, you never get to retire when you want to and on your terms so move on.
Now lets focus on recent performance. Here is the first paragraph from the PR newswire release after the TPIV quarterly update on August 31:
Anticipated 2017 Milestones:
"Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200 Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer Complete enrollment in TapImmune Sponsored Phase 2 study of TPIV 200 in TNBC File amended investigational new drug application (IND) for TPIV 110 for treating HER2/neu+ breast cancer".
There is no reference to Q317 anymore and MAYO has been completely eliminated from this summary. MAYO is now an academic institution whos does not care about TPIV or its shareholders. Really, nice of TPIV to communicate that now it appears we are late again! Also, he mentioned the recent financing as a big accomplishment in Q217, it was dilutive, provided preferrential treatment to 2015 investors via repriced warrants, includes no real lock-up period for new investors, and millions more share potential capped at low share prices. Finally, Wilson also stated the financing was "at market", what? At market very close to 12-month and historic lows (close to $0.30/share pre-reverse split). Wilson and TPIV have zero credibility now, how can you believe anything this company tells you.
In summary, TPIV has a big problem with MAYO, competitors and in-house. The Quarterly Update was pathetic and all deadlines appear to be extended. I still wonder if MAYO trials are a sure thing now. I informed the message board nothing would come from TPIV and Wilson at both the annual meeting and and quarterly update last week and it turned out worse than I thought, TPIV appears to be late on everything. No Mayo influence, late again and amending trials, extending schedule and costing more money. As a result, more financing will needed sooner rather than later, more dilution will occur which equals more shareholder value destruction while risk for private investors is mitigated via additional warrant repricing. I would not touch this stock with 100 foot pole. Management changes needed now! This stock is going to slide down to $0.50 to $1/share reflecting csh value or less until new management is in place and real data and real progress is reported. Do not be suckered into buying this stock, you are giving your money to help protect downside for the private investors and to let village idiot remain employed. This is a complete disaster at present.
News 
Market Data 
Discover 
AI
